Drug intelligence / Profile preview

RS_002

Development stage: Preclinical
Lead developer: Redesign Science
Modality: Small Molecules

Overview

RS_002 is a preclinical small molecule Targeted Protein Interaction Modulator (TPIM™) being developed by Redesign Science for the treatment of solid tumors. Developed using the company's NUVO™ technology platform, RS_002 is designed to modulate protein-protein interactions mediated by exchange factors. By targeting these specific exchange factors, the drug aims to disrupt oncogenic signaling pathways involved in tumor growth and progression. As of early 2024, the program is in the hit-to-lead stage of preclinical development.

Beyond the preview

Go deeper on RS_002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RS_002.

Explore the full profile